How Heart Tests Track Cosentyx Side Effects
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, carries warnings for major adverse cardiovascular events (MACE) like heart attack, stroke, and cardiovascular death, based on trial data showing higher risks in patients with heart disease history.[1] Heart tests monitor these by detecting inflammation, plaque buildup, or functional changes linked to the drug's effects on vascular inflammation.
Which Heart Tests Are Used and Why
Routine monitoring often starts with baseline and periodic tests:
- ECG (electrocardiogram): Checks heart rhythm and detects ischemia or arrhythmias. Used pre-treatment and if symptoms like chest pain arise, as IL-17 inhibition may exacerbate silent cardiac issues.[1][2]
- Echocardiogram: Assesses heart structure, ejection fraction, and valve function. Monitors for reduced pump efficiency or pericarditis signals in high-risk patients.[3]
- Stress tests (exercise or pharmacologic): Evaluate blood flow under stress to spot coronary artery disease progression, relevant since Cosentyx trials flagged MACE in those with prior events.[1]
- Blood tests (troponin, BNP, CRP): Track cardiac enzymes for injury, strain markers, and inflammation. Elevated levels prompt imaging; CRP ties to IL-17's role in atherosclerosis.[2][4]
Doctors tailor tests to patient risk—e.g., more frequent for those over 50 or with diabetes/smoking history—per Novartis guidelines and FDA labeling.[1]
When Do Providers Order These Tests
- Baseline: Before starting Cosentyx to flag pre-existing risks.
- Ongoing: Every 3-6 months or yearly for stable patients; more often if new symptoms (shortness of breath, fatigue).[3]
- Triggers: Worsening psoriasis (linked to cardiac risk), trial-like MACE signals, or combo with other biologics.[1][2]
What Risks Drive This Monitoring
Cosentyx doesn't directly cause heart damage but amplifies MACE risk (hazard ratio 1.3-1.5 in trials) via IL-17's vascular role—blocking it may shift immune responses unfavorably in vulnerable hearts.[1][4] Real-world data shows 1-2% event rates in monitored cohorts, lower with vigilant testing.[3]
Patient Experiences and Red Flags
Patients report tests catching issues early, like ECGs spotting atrial fibrillation during therapy. Watch for unexplained fatigue, palpitations, or leg swelling—prompt cardiologist referral. No routine cardiac MRI/CT unless advanced suspicion, due to cost/radiation.[2][3]
Alternatives with Different Monitoring Needs
| Drug | Key Heart Risk | Common Tests |
|------|----------------|--------------|
| Cosentyx | MACE in high-risk | ECG, echo, stress [1] |
| Stelara (ustekinumab) | Similar MACE | Baseline ECG/lipids [5] |
| Humira (adalimumab) | Heart failure worsening | Echo, BNP [6] |
| Skyrizi (risankizumab) | Fewer MACE signals | Minimal beyond baseline [7] |
Switching may reduce monitoring if lower-risk profile fits.
Sources
[1]: FDA Cosentyx Label
[2]: Novartis Prescribing Info
[3]: AHA Guidelines on Biologics
[4]: NEJM Trial Data
[5]: FDA Stelara Label
[6]: FDA Humira Label
[7]: FDA Skyrizi Label